Safi Biotherapeutics is working to manufacture inexpensive red blood cells at scale. The company has received more than $16 million from the U.S. Department of Defense and on Wednesday announced a $5 ...
Developer of world-leading capabilities in the hyper-efficient production of manufactured red blood cells at viable economics. The challenge has been whether we can make enough of these cells cheaply ...
CAMBRIDGE, MA, UNITED STATES, January 5, 2024 /EINPresswire.com/ -- Safi Biotherapeutics (“Safi”), a leader in the field of allogeneic biomanufacture of blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results